Company news

PolyPid Ltd. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

PolyPid Provides Positive Regulatory Update for D-PLEX₁₀₀ for the Prevention of Surgical Site Infections in Abdominal Colorectal Surgery

January 23, 2023

PolyPid Announces Publication in the American Journal of Surgery of Phase 2 Clinical Trial Post-hoc Analysis for D-PLEX₁₀₀ in the Prevention of Surgical Site Infections in Abdominal Surgery

January 2, 2023

PolyPid Announces Scheduling of Type D Meeting with U.S. FDA to Discuss SHIELD I Phase 3 Results and Regulatory Pathway for D-PLEX₁₀₀ for the Prevention of Surgical Site Infections in Abdominal Colorectal Surgery

December 11, 2022

PolyPid Announces Receipt of Nasdaq Minimum Bid Price Notification

December 8, 2022

PolyPid Announces Presentation of Phase 2 D-PLEX₁₀₀ Clinical Data at the First Triennial Meeting of the International Orthopaedic Trauma Association

November 28, 2022

PolyPid Provides Corporate Update and Reports Third Quarter 2022 Financial Results

November 8, 2022

PolyPid to Report Third Quarter 2022 Financial Results and Operational Highlights on November 9, 2022

October 25, 2022

PolyPid Announces Cost Reduction Plan

October 19, 2022

PolyPid Announces Eligibility for European Medicines Agency Centralized Procedure for D-PLEX₁₀₀ for the Prevention of Surgical Site Infections in Abdominal Surgery

September 27, 2022

PolyPid Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Results for D-PLEX₁₀₀ in the Prevention of Surgical Site Infections in Abdominal Surgery

September 18, 2022

PolyPid Announces Presentation of Phase 2 D-PLEX₁₀₀ Clinical Data at the European Society for Coloproctology Scientific Conference

September 11, 2022

PolyPid Announces Top-line Results of Phase 3 SHIELD I Trial of D-PLEX₁₀₀ for the Prevention of Surgical Site Infections in Abdominal Surgery

September 1, 2022

PolyPid Announces Presentation at the 2022 Military Health System Research Symposium

August 29, 2022

PolyPid Provides Corporate Update and Reports Second Quarter 2022 Financial Results

August 9, 2022

PolyPid Announces Exclusive Licensing Agreement with ADVANZ PHARMA for the Commercialization of D-PLEX₁₀₀ in Europe

August 2, 2022

PolyPid to Report Second Quarter 2022 Financial Results and Operational Highlights on August 10, 2022

July 26, 2022

PolyPid Announces Presentation of Phase 2 D-PLEX₁₀₀ Clinical Data at the Midwest Surgical Association 2022 Annual Meeting

July 24, 2022

PolyPid Announces Dikla Czaczkes Akselbrad Assumes Role of CEO

July 4, 2022

PolyPid Announces Presentation of D-PLEX₁₀₀ Phase 2 Clinical Data at ASM Microbe 2022

June 5, 2022

PolyPid Announces Publication of Animal Model Studies in 2022 ASCO Annual Meeting Abstract Demonstrating that Locally Administered OncoPLEX Potentially Decreases the Likelihood of Tumor Recurrence with Reduced Side Effects

May 31, 2022

PolyPid Announces Completion of Enrollment in Phase 3 SHIELD I Trial of D-PLEX₁₀₀ for Prevention of Surgical Site Infections in Abdominal Surgery

May 30, 2022

PolyPid Announces Recommendation by Data Safety Monitoring Board to Conclude Enrollment of Phase 3 SHIELD I Trial of D-PLEX₁₀₀ at the Minimum Number of Patients Targeted Following Unblinded Interim Efficacy Analysis

May 22, 2022

PolyPid Provides Corporate Update and Reports First Quarter 2022 Financial Results

May 10, 2022

PolyPid Announces Presentation of Clinical Data at Surgical Infection Society 2022 Annual Meeting

April 11, 2022

PolyPid Secures $15 Million Non-Dilutive Secured Term Loan Facility

April 5, 2022

PolyPid Announces 750th Patient Enrolled in SHIELD I Phase 3 Clinical Trial of D-PLEX₁₀₀ in Abdominal Surgery

March 1, 2022

PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2021 Financial Results

February 8, 2022

PolyPid Appoints UCSF Brain Tumor Center Director Mitchel S. Berger, M.D., to Oncology Advisory Board

January 3, 2022

PolyPid Announces Planned CEO Transition

January 2, 2022

PolyPid Announces 500th Patient Enrolled in SHIELD I Phase 3 Clinical Trial of D-PLEX₁₀₀ in Abdominal Surgery

November 17, 2021

PolyPid Appoints New Oncology Advisory Board Member

November 15, 2021

PolyPid Announces Positive Preclinical Data of its Intra-tumoral OncoPLEX in Brain Cancer

September 12, 2021

PolyPid Strengthens Executive Team, Appointing Dr. Anthony Senagore as Senior Medical Director

July 11, 2021

PolyPid Announces Positive FDA Type B Meeting Feedback for D-PLEX₁₀₀ Development Program

May 18, 2021

PolyPid Announces 100th Patient Enrolled in SHIELD I Phase 3 Clinical Trial of D-PLEX₁₀₀ for the Prevention of Post-Abdominal Surgery Incisional Infections

February 15, 2021

PolyPid Ltd. Provides Corporate Update and Reports Fourth Quarter and Full-Year 2020 Financial Results

February 9, 2021

PolyPid Announces Positive Preclinical Data from OncoPLEX Intra-Tumoral Cancer Therapy Program

December 21, 2020

PolyPid Initiates SHIELD II: Second Phase 3 Clinical Trial of D-PLEX₁₀₀ for the Prevention of Post-Abdominal Surgery Incisional Infections

December 15, 2020

PolyPid Granted Breakthrough Therapy Designation from FDA for D-PLEX₁₀₀ for the Prevention of Surgical Site Infections in Colorectal Surgery

November 23, 2020

PolyPid Ltd. Provides Corporate Update and Reports Third Quarter 2020 Financial Results

November 10, 2020

PolyPid Ltd. Provides Corporate Update and Reports Second Quarter 2020 Financial Results

August 18, 2020

PolyPid Granted Fast Track Designation from FDA for D-PLEX₁₀₀ for Prevention of Surgical Site Infections in Abdominal Surgery

August 2, 2020

PolyPid Initiates First Phase 3 Clinical Trial of D-PLEX100 for the Prevention of Post-Abdominal Surgery Incisional Infections

June 30, 2020

PolyPid Ltd. Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

June 29, 2020

← Newer news releases

Calls

The 5 newest of 22 calls. Every call is listed under its year.

Decks

The 5 newest of 7 decks. Every deck is listed under its year.